Bispecific molecules for use in inducing antibody dependent effector cell-mediated cytotoxicity
AssigneeMedarex, Inc.
InventorsEdward D. Ball, Michael W. Fanger
Life of this patent
Estimating the term…
Abstract
Bispecific molecules comprising a non-immunoglobulin tumor cell specific ligand and an antibody which binds the Fc receptor of an effector cell at a site that is not inhibited by endogenous immunoglobulin are disclosed. The bispecific molecules can be used to induce a specific antibody dependent effector cell-mediated cytotoxicity against tumor cells, such as small cell lung carcinoma (SCLC) cells, either in vivo or in vitro.
Claims8
A tumor cell-specific effector cell comprising:
- (i) an effector cell;
- (ii) a non-immunoglobulin tumor cell-specific ligand;
- and
- (iii) an antibody selected from the group consisting of:
- mAb22 produced by the hybridoma having ATCC Accession number HB12147 and mAb32 produced by the hybridoma having ATCC number HB9469.
A method of inducing a specific antibody dependent effector cell-mediated cytotoxicity against a tumor cell, in a subject, comprising administering to the subject a bispecific molecule comprising (a) a non-immunoglobulin tumor cell-specific ligand, and (b) an antibody selected from the group consisting of:
- mAb22 produced by the hybridoma having ATCC Accession number HB12147 and mAb32 produced by the hybridoma having ATCC number HB9469.
A bispecific molecule comprising a non-immunoglobulin tumor cell-specific ligand and an antibody selected from the group consisting of:
- mAb22 produced by the hybridoma having ATCC Accession number HB12147 and mAb32 produced by the hybridoma having ATCC number HB9469.
A bispecific molecule comprising bombesin or an analogue thereof and mAb22 produced by the hybridoma having ATCC Accession number HB12147.
A bispecific molecule comprising bombesin or an analogue thereof and mAb32 produced by the hybridoma having ATCC Accession number HB9469.
Dependencies are inferred from the claim text.